R
Richard Kaplan
Researcher at University College London
Publications - 226
Citations - 36795
Richard Kaplan is an academic researcher from University College London. The author has contributed to research in topics: Cancer & Clinical trial. The author has an hindex of 56, co-authored 215 publications receiving 34004 citations. Previous affiliations of Richard Kaplan include University College Hospital & University of Miami.
Papers
More filters
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
New guidelines to evaluate the response to treatment in solid tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: In this article, the authors proposed a model by which a combined assessment of all existing lesions, characterized by target lesions (to be measured) and nontarget lesions, is used to extrapolate an overall response to treatment.
Journal ArticleDOI
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
Hashim U. Ahmed,Hashim U. Ahmed,Ahmed El-Shater Bosaily,Ahmed El-Shater Bosaily,Louise Brown,Rhian Gabe,Richard Kaplan,Mahesh K.B. Parmar,Yolanda Collaco-Moraes,Katie Ward,Richard Hindley,Alex Freeman,Alex Kirkham,Robert Oldroyd,Chris Parker,Mark Emberton,Mark Emberton +16 more
TL;DR: Using MP-MRI to triage men might allow 27% of patients avoid a primary biopsy and diagnosis of 5% fewer clinically insignificant cancers, as well as reduce unnecessary biopsies by a quarter.
Journal ArticleDOI
Consensus statement: Guidelines for PSA following radiation therapy
Journal ArticleDOI
Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
Glenn J. Bubley,Michael A. Carducci,William L. Dahut,Nancy A. Dawson,Danai Daliani,Mario A. Eisenberger,William D. Figg,Boris Freidlin,Susan Halabi,Gary R. Hudes,Maha Hussain,Richard Kaplan,Charles E. Myers,William Oh,Daniel P. Petrylak,Eddie Reed,Bruce J. Roth,Oliver Sartor,Howard I. Scher,Jonathan W. Simons,V. J. Sinibaldi,Eric J. Small,Matthew R. Smith,Donald L. Trump,Robin T. Vollmer,George Wilding +25 more
TL;DR: The purpose of determining the number of patients whose PSA level drops in a phase II trial of AIPC is to guide the selection of agents for further testing and phase III trials and developed practical guidelines for using PSA as a measurement of outcome.